KR101941724B1 - 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자 - Google Patents

계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자 Download PDF

Info

Publication number
KR101941724B1
KR101941724B1 KR1020137035132A KR20137035132A KR101941724B1 KR 101941724 B1 KR101941724 B1 KR 101941724B1 KR 1020137035132 A KR1020137035132 A KR 1020137035132A KR 20137035132 A KR20137035132 A KR 20137035132A KR 101941724 B1 KR101941724 B1 KR 101941724B1
Authority
KR
South Korea
Prior art keywords
seq
ser
gly
region
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137035132A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095017A (ko
Inventor
테오도루스 헨드리쿠스 자코부스 곽스
다비드 에이.티.엠. 주이즈게스트
로날드 보겔스
로버트 하인즈 에드워드 프리젠
Original Assignee
얀센 백신스 앤드 프리벤션 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 백신스 앤드 프리벤션 비.브이. filed Critical 얀센 백신스 앤드 프리벤션 비.브이.
Publication of KR20140095017A publication Critical patent/KR20140095017A/ko
Application granted granted Critical
Publication of KR101941724B1 publication Critical patent/KR101941724B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
KR1020137035132A 2011-07-14 2012-07-12 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자 Active KR101941724B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161572417P 2011-07-14 2011-07-14
EP11173953 2011-07-14
US61/572,417 2011-07-14
EP11173953.8 2011-07-14
PCT/EP2012/063637 WO2013007770A1 (en) 2011-07-14 2012-07-12 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses

Publications (2)

Publication Number Publication Date
KR20140095017A KR20140095017A (ko) 2014-07-31
KR101941724B1 true KR101941724B1 (ko) 2019-01-23

Family

ID=47505543

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137035132A Active KR101941724B1 (ko) 2011-07-14 2012-07-12 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자

Country Status (18)

Country Link
US (2) US8961978B2 (cg-RX-API-DMAC7.html)
EP (1) EP2731967B1 (cg-RX-API-DMAC7.html)
JP (1) JP5683752B2 (cg-RX-API-DMAC7.html)
KR (1) KR101941724B1 (cg-RX-API-DMAC7.html)
CN (1) CN103906763B (cg-RX-API-DMAC7.html)
AU (1) AU2012282504B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014000263B1 (cg-RX-API-DMAC7.html)
CA (1) CA2838999C (cg-RX-API-DMAC7.html)
DK (1) DK2731967T3 (cg-RX-API-DMAC7.html)
EA (1) EA027054B1 (cg-RX-API-DMAC7.html)
ES (1) ES2608321T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161740T1 (cg-RX-API-DMAC7.html)
IL (1) IL230222A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN00953A (cg-RX-API-DMAC7.html)
MX (1) MX346206B (cg-RX-API-DMAC7.html)
MY (1) MY166282A (cg-RX-API-DMAC7.html)
PH (1) PH12013502479A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013007770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
IN2014CN04742A (cg-RX-API-DMAC7.html) 2011-11-28 2015-09-18 Crucell Holland Bv
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
IL241552B2 (en) * 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN105452270B (zh) 2013-05-30 2020-12-01 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
RU2682049C2 (ru) * 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
AU2015214146B2 (en) * 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
MX2016012530A (es) 2014-03-27 2017-01-05 Genentech Inc Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
WO2016005480A1 (en) 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
KR102463632B1 (ko) 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CA2975655C (en) * 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
US10174127B2 (en) 2015-02-05 2019-01-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
US11135282B2 (en) * 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
AU2016261299B2 (en) 2015-05-11 2019-12-05 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2019502715A (ja) 2016-01-13 2019-01-31 メディミューン，エルエルシー Ａ型インフルエンザを治療する方法
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2018038096A1 (ja) * 2016-08-23 2018-03-01 国立大学法人東京大学 モノクローナル抗体又はその抗原結合フラグメント及びその使用
JP2020500169A (ja) 2016-10-27 2020-01-09 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスを中和する化合物
CA3051377A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
US11040963B2 (en) 2017-02-02 2021-06-22 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibitions
TW201837170A (zh) 2017-02-28 2018-10-16 賓州大學委員會 新穎ａａｖ媒介的流感疫苗
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
PL3743106T3 (pl) 2018-01-23 2022-11-14 Janssen Vaccines & Prevention B.V. Szczepionki przeciwko wirusowi grypy i ich zastosowanie
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP7865873B2 (ja) 2019-09-05 2026-05-26 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
US20240043416A1 (en) 2021-02-04 2024-02-08 Sichuan Haisco Pharmaceutical Co., Ltd. Salt and crystal form of ha inhibitor compound
EP4508077A4 (en) * 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
US20260183380A1 (en) 2022-11-14 2026-07-02 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
TW202527960A (zh) 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾ｂ型流感血球凝集素多肽及核酸及其用途
WO2026022067A1 (en) 2024-07-20 2026-01-29 Leyden Laboratories B.V. Neutralising antibodies against influenza viruses
WO2026027730A1 (en) 2024-07-31 2026-02-05 Sanofi Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
WO2026052773A1 (en) 2024-09-06 2026-03-12 Sanofi Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
ES2378272T3 (es) 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
US7329530B2 (en) 2001-06-15 2008-02-12 Crucell Holland B.V. Chimaeric phages
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications 2010, 403:247-251.*
Vaccine 2008, 26, 6068-6076.*

Also Published As

Publication number Publication date
DK2731967T3 (en) 2017-01-16
US20150274811A1 (en) 2015-10-01
EP2731967B1 (en) 2016-10-12
EA027054B1 (ru) 2017-06-30
MX346206B (es) 2017-03-09
BR112014000263A2 (pt) 2017-02-14
ES2608321T3 (es) 2017-04-07
CA2838999A1 (en) 2013-01-17
PH12013502479A1 (en) 2014-01-20
MY166282A (en) 2018-06-25
EA201490288A1 (ru) 2014-05-30
NZ618530A (en) 2016-05-27
KR20140095017A (ko) 2014-07-31
AU2012282504B2 (en) 2017-07-20
CN103906763A (zh) 2014-07-02
US9593159B2 (en) 2017-03-14
AU2012282504A1 (en) 2014-02-06
CN103906763B (zh) 2016-10-12
WO2013007770A1 (en) 2013-01-17
JP5683752B2 (ja) 2015-03-11
BR112014000263B1 (pt) 2022-01-18
CA2838999C (en) 2021-02-16
MX2014000373A (es) 2014-03-31
IL230222A (en) 2017-09-28
IN2014CN00953A (cg-RX-API-DMAC7.html) 2015-04-10
HRP20161740T1 (hr) 2017-02-10
EP2731967A1 (en) 2014-05-21
US20140120113A1 (en) 2014-05-01
JP2014527403A (ja) 2014-10-16
US8961978B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
JP5813629B2 (ja) インフルエンザウイルスｈ３ｎ２を中和可能なヒト抗体及び／または抗原結合フラグメントおよびその使用
AU2012282504B2 (en) Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
KR101485197B1 (ko) 인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
CN101541832B (zh) 能中和流感病毒h5n1的人结合分子及其应用
AU2006290736A1 (en) Method for preparing immunoglobulin libraries
DK2455399T3 (da) Humane bindingsmolekyler, der er i stand til at neutralisere influenzavirus h5n1, og anvendelser deraf
NZ618530B2 (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20211215

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000